Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Purchases of Investments

Cash used to buy marketable securities and other investments.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Purchases of Investments · Q3 FY2026 · quarter ended Sep 2026

Purchases of investments grows, but more slowly than its trailing trend

Q3 FY2026 purchases of investments of $138.28M (cash outflow) rose 86.4% year over year, behind the +143.8% change in trailing-twelve-month purchases of investments. Sequentially, it fell 69.1% from the prior quarter. Over 3 fiscal years it compounded at +136.5% a year.

Context

  • Purchases of investments grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +86.4% toward the trailing-twelve-month pace of +143.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$138.28M-69.1% QoQ
Last fiscal yearDec 2025
-$522.21M-12.9% YoY
LTMSep 2026
-$1.01B+143.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.4%——
1 year-12.9%——
3-year CAGR+136.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(522.21M) USD
Year-over-year change
+12.9%

Purchases of Investments vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +143.8% is the highest of 6, against a peer median of -37.4%.
  • Purchases of investments amounts to 1114.4% of revenue for SYRE, versus a peer median of 972.9%.
SYRE Competitors
Purchases of Investments for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$1.01B USD+143.8%+136.5%1114.4%
ARDXArdelyx, Inc.LTM Mar 2026$235.25M USD+22.1%+63.2%55.0%
UPBUpstream Bio, Inc.LTM Mar 2026$134.24M USD-74.8%—4041.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81.41M USD-37.4%-37.8%972.9%
ANABAnaptysBio, Inc.LTM Mar 2026$73.86M USD-83.4%-37.4%31.8%
IFRXInflaRx N.V.LTM Mar 2026€46.43M EUR+46.1%-11.8%158301.3%
ABVXAbivax S.A.FY2025€13.59M EUR—+207.0%—
IMUXImmunic, Inc.LTM Mar 2026$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —-37.4%-11.8%972.9%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.